TP1L
TP1L is a potent and selective T-cell protein tyrosine phosphatase (TC-PTP) PROTAC degrader, with a DC50 value of 35.8 nM. TP1L elevates the phosphorylation level of TC-PTP substrates including pSTAT1 and pJAK1. TP1L selectively enhances IFN-γ signaling and increases MHC-I expression. TP1L activates TCR signaling through increases phosphorylation of LCK. TP1L enhances CAR-T cell mediated tumor killing efficacy through activation of the CAR-T cells. TP1L can be used for the study of cancer. (Pink: TC-PTP ligand: (HY-138964), Blue: E3 ligase CRBN Ligand (HY-A0003), Black: Linker: (HY-140002)).
(Pink: TC-PTP ligand (HY-138964); Blue: Cereblon ligand (HY-A0003); Black: linker (HY-140002)).
For research use only. We do not sell to patients.
- Formula: C64H81F2N8O14P
- Molecular Weight:1255.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
In Vitro
TP1L (0.5-4000 nM, 3-24 h) selectively degrades TC-PTP depends on the ubiquitination-proteasome pathway (DC50 = 35.8 nM) in HEK293 cells[1].
TP1L (< 10 μM) shows no significant inhibition towards other PTPs even at up to 10 μM TP1L concentration[1].
TP1L (3.9-4000 nM, 16 h) selectively enhances IFN-γ signaling and promotes antigen presentation in HEK293 cells[1].
TP1L (62.5-1000 nM, 16 h) elevates pLCK in Jurkat T-cells and enhances CAR-T cells killing efficiency in a KB tumor/CAR-T cell coculture system [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HEK293 cells and Jurkat T-cells
-
Concentration:0.5, 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500, 1000, 2000, 4000 nM
-
Incubation Time:3, 6, 16, 24 h
-
Result:Degradated TC-PTP with a DC50 of 35.8 nM in HEK293 cells after 16 hours of treatment.
Showed no signicantly altered on the level of PTP1Bat up to 4 mM concentration.
Degradated TC-PTP completly within 6 hours.
Did not decrease during the entire period of TP1L treatment.
Enhanced the levels of pJAK1 and pSTAT1.
Did not affected the phosphorylation level of JAK2, which is a substrate of PTP1B.
Degraded TC-PTP and promoted phosphorylation of LCK in Jurkat T-cells.
Chemical Information
-
Molecular Weight 1255.34
-
Formula C64H81F2N8O14P
-
SMILES
FC(C1=CC=C(C[C@H](NC([C@@H](NC(CO[C@@H]2[C@@H](C(C)C)CC[C@H](C)C2)=O)CC3=CC=CC=C3)=O)C(N[C@@H](CCCCNC(C4=CC=C(CC)C=C4)=O)C(NCCOCCC(NC5=CC=CC6=C5CN(C(CC7)C(NC7=O)=O)C6=O)=O)=O)=O)C=C1)(P(O)(O)=O)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)